Results 21 to 30 of about 1,097,021 (302)

Immune Checkpoint Inhibitors [PDF]

open access: yes, 2023
Immune Checkpoint Inhibitors - New Insights and Recent Progress explores a vast array of subjects related to immune checkpoint inhibitors and presents novel insights in this emerging field.

core   +1 more source

Checkpoint Inhibitors [PDF]

open access: yesDeutsches Ärzteblatt international, 2019
Treatment with checkpoint inhibitors such as anti-programmed death-1 (anti-PD-1), anti-PD-ligand 1 (anti-PD-L1), and anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) antibodies can prolong the survival of cancer patients, but it also induces autoimmune side effects in 86-96% of patients by activating the immune system.
Lucie, Heinzerling   +4 more
openaire   +2 more sources

[Checkpoint inhibitors-indications and application in melanoma patients]. [PDF]

open access: yes, 2020
Since its introduction in 2011 the checkpoint inhibitor ipilimumab, has revolutionized the whole of oncology. After this first major step more checkpoint inhibitors, such as the PD‑1 antibodies nivolumab and pembrolizumab have been developed. The results
Lamos, Cristina   +5 more
core   +2 more sources

Checkpoint inhibitors and arthritis [PDF]

open access: yesAnnals of the Rheumatic Diseases, 2019
It was with interest that we read the article by Belkhir et al 1 in the recent Annals of Rheumatic Disease . The article described the first report of rheumatoid arthritis (RA) and polymyalgia rheumatica developing after the use of immune checkpoint inhibitors to treat a variety of cancers.
Nicholas, Manolios, Leslie, Schrieber
openaire   +2 more sources

Keeping Checkpoint Inhibitors in Check [PDF]

open access: yesJAMA Network Open, 2019
No ...
Catenacci, Daniel V.T.   +2 more
openaire   +3 more sources

Structure and Optimization of Checkpoint Inhibitors [PDF]

open access: yesCancers, 2019
With the advent of checkpoint inhibitor treatment for various cancer types, the optimization of drug selection, pharmacokinetics and biomarker assays is an urgent and as yet unresolved dilemma for clinicians, pharmaceutical companies and researchers.
Picardo, Sarah L.   +2 more
openaire   +4 more sources

Immune checkpoint inhibitors in malignancy [PDF]

open access: yesAustralian Prescriber, 2019
Immune checkpoints normally stop the body from mounting an immune response against healthy cells. Some cancers can acquire these checkpoints so that the tumour cells are not recognised by the immune systemInhibiting the checkpoints therefore enables the tumour cells to be recognised and allows an immune response to be activated against themImmune ...
Luke, Ardolino, Anthony, Joshua
openaire   +2 more sources

Bub1 is a fission yeast kinetochore scaffold protein, and is sufficient to recruit other spindle checkpoint proteins to ectopic sites on chromosomes [PDF]

open access: yes, 2007
The spindle checkpoint delays anaphase onset until all chromosomes have attached in a bi-polar manner to the mitotic spindle. Mad and Bub proteins are recruited to unattached kinetochores, and generate diffusible anaphase inhibitors.
Rischitor, Patricia E   +8 more
core   +2 more sources

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management

open access: yesKidney Medicine, 2021
Immune checkpoint inhibitors are now approved for more than 50 indications, and increasing numbers of patients with advanced cancer are receiving immunotherapy.
Harish Seethapathy   +2 more
doaj   +1 more source

DNA replication is required for the checkpoint response to damaged DNA in Xenopus egg extracts. [PDF]

open access: yes, 2002
Alkylating agents, such as methyl methanesulfonate (MMS), damage DNA and activate the DNA damage checkpoint. Although many of the checkpoint proteins that transduce damage signals have been identified and characterized, the mechanism that senses the ...
Lindsay, Howard D.   +3 more
core   +5 more sources

Home - About - Disclaimer - Privacy